Skip to main
SANA
SANA logo

Sana Biotechnology (SANA) Stock Forecast & Price Target

Sana Biotechnology (SANA) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 71%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Sana Biotechnology Inc. is positioned favorably within the expanding biologics market, which experienced a growth rate of 32% from 2022 to 2023 in both the US and EU5. The company’s development of cell therapies, particularly SG299, is expected to drive market uptake due to its increased accessibility, lower cost, and absence of lymphodepletion requirements, surpassing projections for traditional ex vivo cell therapies. Furthermore, the observed 40% increase in biologics usage among patients with systemic lupus erythematosus (SLE) highlights an increasing acceptance and demand for innovative treatment options, reinforcing the positive outlook for Sana Biotechnology's stock.

Bears say

Sana Biotechnology Inc. faces significant uncertainties regarding the efficacy and safety of its lead programs, which could severely hinder their development and market uptake. Additionally, the associated health risks of conditions targeted by the company's therapies, such as high rates of kidney failure and elevated mortality rates, pose considerable challenges for patient outcomes and can adversely affect public perception and adoption of its treatments. Furthermore, persistent difficulties in glucose management for conditions like Type 1 diabetes highlight the complexity of the challenges Sana seeks to address, potentially complicating the viability of its therapeutic approaches in achieving commercial success.

Sana Biotechnology (SANA) has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 71% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sana Biotechnology and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sana Biotechnology (SANA) Forecast

Analysts have given Sana Biotechnology (SANA) a Buy based on their latest research and market trends.

According to 7 analysts, Sana Biotechnology (SANA) has a Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sana Biotechnology (SANA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.